Raf kinases: Oncogenesis and drug discovery
โ Scribed by Ralf Schreck; Ulf R. Rapp
- Book ID
- 102272724
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- French
- Weight
- 308 KB
- Volume
- 119
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
โฆ Synopsis
Abstract
Raf kinase signaling has been thoroughly investigated over the last 20 years. AโRaf, BโRaf and CโRaf, the 3 mammalian members of the Raf family, are involved in a variety of cellular processes such as growth, proliferation, survival, differentiation and transformation. The detection of BโRAF mutations in a wide variety of human cancers, the description of wildtype and mutant BโRAF as tumor antigens in melanoma and the promising outcome of clinical trials evaluating the Raf inhibitor Nexavarยฎ (Sorafenib, BAY 43โ9006) have sparked a broad interest in the scientific community. After a short historical detour and an introduction into Raf kinase signaling, we are going to discuss here recent outcomes of Raf kinase research with respect to tumor formation and give an overview on current efforts to develop anticancer therapies interfering with aberrant Raf kinase signaling. ยฉ 2006 WileyโLiss, Inc.
๐ SIMILAR VOLUMES
Protein tyrosine kinases (PTKs) play a crucial role in many cell regulatory processes. It is therefore not surprising to see that functional perturbation of PTKs results in many diseases. Despite the diverse primary structure organization of various PTKs, the catalytic or kinase domains of various P
Drug Discovery and Development, edited by M.S. Chorghade, is a two volume set, the first of which is now available. Volume 1, Drug Discovery, is composed of 16 chapters by authors who are active in the field of medicinal chemistry and are able to bring historical perspective to this important field